Search hospitals > Illinois > Urbana
Carle Cancer Institute
Claim this profileUrbana, Illinois 61801
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Lymphoma
Conducts research for B-Cell Lymphoma
Conducts research for Non-Hodgkin's Lymphoma
Conducts research for Diffuse Large B-Cell Lymphoma
6 reported clinical trials
3 medical researchers
Summary
Carle Cancer Institute is a medical facility located in Urbana, Illinois. This center is recognized for care of Non-Small Cell Lung Cancer, Lymphoma, B-Cell Lymphoma, Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma and other specialties. Carle Cancer Institute is involved with conducting 6 clinical trials across 15 conditions. There are 3 research doctors associated with this hospital, such as Maria T. Grosse-Perdekamp, Kendrith Rowland, MD, and Daniel H. Barnett.Area of expertise
1Non-Small Cell Lung Cancer
Stage IV
Stage III
EGFR positive
2Lymphoma
CD20 positive
MYC positive
BCL-2 positive
Top PIs
Maria T. Grosse-PerdekampCarle Cancer Center2 years of reported clinical research
Expert in Breast Cancer
Studies Cancer
29 reported clinical trials
60 drugs studied
Kendrith Rowland, MDCarle Cancer Center2 years of reported clinical research
Expert in Cancer
Studies Breast Cancer
30 reported clinical trials
61 drugs studied
Daniel H. BarnettCarle Cancer Center2 years of reported clinical research
Studies Cancer
Studies Tumors
11 reported clinical trials
40 drugs studied
Clinical Trials running at Carle Cancer Institute
Breast Cancer
Renal Cell Carcinoma
Non-Small Cell Lung Cancer
Lymphoma
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Diffuse Large B-Cell Lymphoma
Cancer
Kidney Cancer
Triple-Negative Breast Carcinoma
Combination Therapy
for Breast Cancer
This is an open-label, phase I/II double arm study of the SV-BR-1-GM regimen in combination with retifanlimab in patients with metastatic or locally recurrent breast cancer who have failed standard therapy. Patients will receive the SV-BR-1-GM regimen with combination immunotherapy. There will be an initial evaluation of the combination of the SV-BR-1-GM regimen with retifanlimab every 3 weeks. If this is found to be safe and well tolerated in a cohort of at least 12 patients (dose-limiting toxicities (DLTs) in less than 30% of the patients evaluated), then an expansion cohort of up to 24 patients will be treated with that combination. These will be randomized to two regimens differing in the timing of checkpoint inhibitor administration.
Recruiting1 award Phase 1 & 23 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Carle Cancer Institute?
Carle Cancer Institute is a medical facility located in Urbana, Illinois. This center is recognized for care of Non-Small Cell Lung Cancer, Lymphoma, B-Cell Lymphoma, Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma and other specialties. Carle Cancer Institute is involved with conducting 6 clinical trials across 15 conditions. There are 3 research doctors associated with this hospital, such as Maria T. Grosse-Perdekamp, Kendrith Rowland, MD, and Daniel H. Barnett.